Table 3 Univariate analysis of patients’ PFS of CAR T cells immunotherapy and possible prognostic factors
prognostic factor | case(n) | Median PFS (months) | Mean PFS (months, 95%CL) | 1-year PFS (%, 95%CL) | p-value |
|---|---|---|---|---|---|
Ag recognition moieties | |||||
CD19 | 81 | 10 | 24.11*(18.35–29.87) | 46.12%(34.20–57.22% | |
CD20 | 9 | 12 | 11.5(6.61–16.39) | 33.33%(7.83–62.26%) | 0.3309 |
Disease | |||||
leukemia | 42 | 7 | 20.30*(12.56–28.04) | 40.19%(24.41–55.47%) | |
lymphoma | 48 | 12 | 18.10*(13.37–22.82) | 48.22%(32.68–62.14%) | 0.3123 |
T cell origin | |||||
Autologous | 74 | 12 | 22.33*(16.62–28.04) | 45.60%(33.47–56.92%) | |
Allogeneic | 16 | 3 | 8.41*(5.23–11.59) | 47.73%(22.05–69.64%) | 0.1779 |
Generation | |||||
1st | 11 | 10.4 | 18.52*(9.86–27.18) | 45.45%(16.66–70.69%) | |
2nd | 76 | 10 | 22.69*(16.40–28.98) | 45.41%(33.11–56.91%) | 0.7754 |
costimulatory domains | |||||
CD137 and CD3ζ | 28 | 6 | 16.44*(8.41–24.46) | 33.39%(16.56–51.22%) | |
CD28 and CD3ζ | 46 | – | 14.50*(11.63–17.37) | 56.29%(39.42–70.14%) | 0.0489 |
T cell activation | |||||
OKT3 | 43 | 12 | 12.76(9.80–15.73) | 40.32%(23.45–56.63%) | |
CD3/CD28 beads | 34 | 12.6 | 25.02*(16.78–33.26) | 52.78%(34.90–67.84%) | 0.3961 |
IL-2 to cells | |||||
yes | 57 | 12.6 | 18.91*(14.15–23.67) | 50.10%(35.63–62.95%) | |
no | 28 | 12 | 18.60*(10.86–26.34) | 38.27%(19.56–56.81%) | 0.616 |
transfection methods | |||||
non-viral vector | 6 | 12 | 12.83(7.72–1.94) | 33.33%(4.61–67.56%) | |
viral vector | 94 | 10 | 23.99*(18.34–29.64) | 45.75%(34.12–56.63%) | 0.4634 |
Lymphodepletion | |||||
yes | 53 | 10 | 18.58*(12.16–24.99) | 39.07%(25.16–52.72%) | |
no | 21 | 5 | 8.18*(5.49–10.87) | 37.25%(12.81–62.22%) | 0.3282 |
CART cells | |||||
≥ 108 | 54 | 8 | 21.43*(14.34–28.51) | 42.01%(28.04–55.35%) | |
< 108 | 23 | – | 30.15*(20.10–40.20) | 58.38%(34.69–76.06%) | 0.1471 |
IL-2 administration to patients | |||||
yes | 13 | 12 | 13.44(9.19–17.70) | 29.92%(7.49–57.01%) | |
no | 77 | 10 | 23.05*(16.19–27.05) | 47.06%(34.99–58.22%) | 0.9355 |
T cell persistence time | |||||
≥ 2 months | 44 | 10 | 18.33*(11.34–25.32) | 37.26%(21.95–52.59%) | |
< 2 months | 46 | 12.6 | 18.82*(13.56–24.09) | 50.62%(34.60–64.60%) | 0.2986 |
Peak serum IL-2 level | |||||
≥ 50 pg/mL | 8 | 12 | 12*(7.84–16.16) | 41.67%(7.20–74.73%) | |
< 50 pg/mL | 8 | 9 | 7.78*(3.61–11.94) | 26.25%(1.27–66.37%) | 0.4159 |